权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Developing therapeutic antibodies for Alzheimer's disease

开发阿尔茨海默病的治疗抗体

基本信息

批准号：
10484675
负责人：
Miao Sun
金额：
$ 49.85万
依托单位：
VERSAPEUTICS INC
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-08-01 至 2023-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10484675
关键词：
Adult Agreement Alzheimer&apos s Disease Alzheimer&apos s disease brain Alzheimer&apos s disease model Alzheimer&apos s disease therapeutic American Amyloid Antibodies Antibody Therapy Autopsy Binding Biodistribution Biological Assay Biological Markers Brain Businesses California Clinical Clinical Pathology Data Detection Development Disease Progression Dose Drug Kinetics Enzyme-Linked Immunosorbent Assay Evaluation Future Glutamates Heart Hippocampus (Brain)Human Impaired cognition Individual Injections Intravenous Intravenous Bolus Intravenous infusion procedures Kidney Laboratories Licensing Life Liver Lung Maintenance Measures Mediating Medical Methods Monoclonal Antibodies Mus Neurons Organ Outcome Pathway interactions Penetration Pharmaceutical Preparations Phase Property Rattus Regimen Safety Sampling Serum Small Business Innovation Research Grant Solid Study of serum Synapses Synaptic plasticity Testing Therapeutic Therapeutic Agents Therapeutic antibodies Time TimeLine Tissue Sample Tissues Toxic effect Toxicokinetics Toxicology United States Universities candidate marker caregiving cell bank cognitive function conditional knockout cost design effective therapy efficacy testing experimental study immunogenicity in vivo monomer mouse model nonhuman primate novel novel therapeutic intervention novel therapeutics object recognition planar cell polarity preclinical development preclinical study prevent professor receptor synaptic function synaptogenesis

项目摘要

PROJECT SUMMARY/ABSTRACT Millions of Americans suffer from Alzheimer’s disease and there are currently no therapies available to prevent or slow the progression of the disease. The unmet medical needs of individuals with Alzheimer’s disease result in hundreds of billions of dollars of costs in paid and unpaid caregiving in the United States every year. VersaPeutics is a small business developing novel therapeutics for Alzheimer’s disease. In this Phase I SBIR project we will perform preclinical studies to determine the feasibility of antibody-based therapeutics that are designed to treat Alzheimer’s disease using a unique mechanism of action, by examining pharmacokinetics, efficacy, toxicity and toxicokinetic. At the conclusion of these studies, we will have met several important milestones that will support further preclinical development of our novel therapeutics for Alzheimer’s disease.

项目摘要/摘要数以百万计的美国人患有阿尔茨海默病，目前还没有治疗方法预防或减缓疾病的发展。阿尔茨海默病患者未得到满足的医疗需求每年在美国造成数千亿美元的有偿和无偿护理费用。 VersaPeutics是一家开发治疗阿尔茨海默病的新疗法的小企业。在此阶段I SBIR中我们将进行临床前研究，以确定基于抗体的疗法的可行性，这些疗法旨在使用独特的作用机制，通过检查药代动力学来治疗阿尔茨海默氏症，药效、毒性和毒代动力学。在这些研究的结论中，我们将遇到几个重要的这些里程碑将支持我们治疗阿尔茨海默病的新疗法的进一步临床前开发。